Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts.

Sahasrabuddhe VV, Luhn P, Wentzensen N
Future Microbiol. 2011 6 (9): 1083-98

PMID: 21958146 · PMCID: PMC3809085 · DOI:10.2217/fmb.11.87

While organized screening programs in industrialized countries have significantly reduced cervical cancer incidence, cytology-based screening has several limitations. Equivocal or mildly abnormal Pap tests require costly retesting or diagnostic work-up by colposcopy and biopsy. In low-resource countries, it has been difficult to establish and sustain cytology-based programs. Advances in understanding human papillomavirus biology and the natural history of human papillomavirus-related precancers and cancers have led to the discovery of a range of novel biomarkers in the past decade. In this article, we will discuss the potential role of new biomarkers for primary screening, triage and diagnosis in high-resource countries and their promise for prevention efforts in resource constrained settings.

MeSH Terms (10)

Alphapapillomavirus Biomarkers, Tumor Early Detection of Cancer Female Genes, Viral Humans Mass Screening Molecular Diagnostic Techniques Papillomavirus Infections Uterine Cervical Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: